GENE ONLINE|News &
Opinion
Blog

Bispecific Antibody
F-star Announces Collaboration with Takeda to Develop Next Generation Immunotherapeutics
2023-07-09
Jazz Opts Into License Zymeworks’ Solid Tumor Med With $325 Million Payment
2022-12-21
Biogen To Receive Potential Royalties For Anti-CD20 Bispecific From Genentech
2022-12-20
Summit Bets $5 Billion On Akeso’s Bispecific Antibody
2022-12-07
Regeneron Pays CytomX $2 Billion Biobucks to Develop Bispecific Cancer Therapies Together
2022-11-17
Janssen Scores Another Multiple Myeloma FDA Approval with Tecvayli
2022-10-25
Gilead and MacroGenics Strike Potential $1.7 billion Collaboration Over Bispecific Antibodies
2022-10-17
Europe Okays Roche’s CAR-T Competitor for Blood Cancer
2022-06-09
Sanofi Licenses ABL Bio’s Bispecific Antibody for Parkinson’s Disease
2022-01-13
Sanofi Bets $1 Billion on Preclinical Next-gen Immunotherapies
2021-12-22
ASH 2021: 4 Immunotherapies Highlight Transformations in Blood Cancer Treatment
2021-12-13
Xencor and Janssen Join Forces Against B-cell Lymphoma in a New Billion-Dollar Deal
2021-10-05
Bispecific Antibodies or CAR T-Cells: Which One of These Cancer Immunotherapies Would Prevail?
2021-09-29
J&J’s FDA-Approved Bispecific Antibody Registers Promising Phase 1 Results for a Different Indication
2021-08-20
AbbVie to Acquire TeneoOne and Its Lead Multiple Myeloma Drug
2021-06-27
1 2
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top